Abstract
The idea of delivery of proangiogenic factors to the ischemic region of myocardium or skeletal muscles was proposed more than 30 years ago and abundant preclinical data validate this concept. However, clinical experience with this approach has generally produced unfulfilled promises. Although reestablishment of functional collateral networks for improvement of blood perfusion in ischemic tissues is an undisputed concept for therapeutic intervention, the molecular mechanism underlying collaterogenesis under tissue hypoxia remains poorly understood. Critical issues including the therapeutic efficacy of monotherapy vs. combination with arteriogenic therapy, drug release, optimal dose, and time scale of delivery remain to be resolved. The aim of this review is to discuss molecular mechanisms of angiogenesis and arteriogenesis, to better design clinical trials, and to improve therapeutic efficacy of proangiogenic and arteriogenic factors for the treatment of ischemic diseases.
Citations
Dec 4, 2010·Nature Protocols·Ziquan CaoYihai Cao
Jun 8, 2013·Journal of Translational Medicine·Evgeny K ShevchenkoYelena V Parfyonova
Feb 18, 2011·Expert Opinion on Emerging Drugs·Stefan M Gehrig, Gordon S Lynch
Mar 9, 2010·Experimental Cell Research·Yihai Cao
Aug 27, 2013·Organogenesis·Ektoras Hadjipanayi, Arndt F Schilling
May 7, 2013·Journal of Cardiovascular Pharmacology·Andreas KaratzasNikos E Tsopanoglou
Mar 5, 2016·Oncotarget·Abdel-Majid KhatibGeraldine Siegfried
Jan 8, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Jennifer S FangJanis M Burt
Jun 5, 2020·Science Advances·Ran ZhangXinglu Huang
Mar 1, 2015·Biophysics Reviews·Weihua Song, Xiaomeng Wang
Nov 22, 2011·Nanotechnology·Rituparna Sinha RoyShiladitya Sengupta
Oct 14, 2021·Chemistry, an Asian Journal·Paramita GayenRituparna Sinha Roy
Dec 24, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity